Cetuximab (Erbitux®), a mouse/human chimeric antibody targeting anti-epidermal growth factor receptor (EGFR), received FDA approval for treating wild-type KRAS and EGFR-positive colorectal cancers [2]. The gene discussed is EGFR; the disease is colorectal cancer.